Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

Cataract Clinical Trial

— STAMP  

Official title:

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03832179
• Other study ID #: STAMP
• Status: Recruiting
• Phase: Phase 4
• Start date: November 15, 2018
• Est. completion date: October 30, 2022

Study information

• Verified date: March 2022
• Source: Bay Area Retina Associates
• Contact: Caesar Luo, MD
• Phone: 9259436800
• Email: cluo[@]bayarearetina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

Description:

In patients with pre-existing diabetic macular edema, anti-vascular endothelial growth factor therapy (Bevacizumab, ranibizumab, or aflibercept) will be compared to Ozurdex therapy administered 1 week prior to phacoemulsification cataract extraction. Spectral domain optical coherence tomography and visual acuity will be acquired at 1 week, 1 month, 2 months, and 3 months following cataract surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: October 30, 2022
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years of age

• Gender- All

• Race- All

• Diagnosis of Diabetes (Type 1 or 2) with a concomitant diagnosis of diabetic macular edema as demonstrated on spectral domain optical coherence tomography (Heidelberg Spectralis)

• >250 microns central foveal thickness

• Able and willing to provide informed consent

Exclusion Criteria:

• Significant renal disease

• A condition that in the opinion of the investigator would preclude participation

• Participation in another investigational trial within 30 days of randomization

• Application of focal macular laser within 120 days of enrollment

• Administration of Iluvien implant within 3 years of enrollment

• Administration of intravitreal triamcinolone within 3 months of enrollment

• Administration of any anti-vascular endothelial growth factor agent within 30 days of enrollment

• Known hypersensitivity to any of the investigational products

• Blood pressure >180/110

• Women who are pregnant, lactating, or intend to become pregnant within 1 year of randomization

• Vulnerable populations- including but not limited to wards of the state, cognitively impaired individuals, prisoners, institutionalized individuals

• Individual is planning on moving within 6 months of study enrollment

• Macular edema secondary to cause other than diabetic macular edema

• Ocular condition that, in the opinion of the investigators, may affect course of macular edema during course of study (vein occlusion, uveitis, etc.)

• Evidence of ocular infections

• Evidence of uncontrolled glaucoma

• Known hypersensitivity to any components of bevacizumab, ranibizumab, aflibercept, or Ozurdex

Related Conditions & MeSH terms

• Cataract
• Diabetic Macular Edema
• Edema
• Macular Edema

Intervention

Drug:
• Bevacizumab
Bevacizumab
• Ranibizumab
Ranibizumab
• Aflibercept
Aflibercept
• Ozurdex
Ozurdex

Locations

Country	Name	City	State
United States	Bay Area Retina Associates	Walnut Creek	California

Sponsors (2)

Lead Sponsor	Collaborator
Bay Area Retina Associates	Allergan

Country where clinical trial is conducted

United States, 

References & Publications (11)

Calvo P, Ferreras A, Al Adel F, Dangboon W, Brent MH. EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY. Retina. 2018 Mar;38(3):490-496. doi: 10.1097/IAE.0000000000001552. — View Citation

Dong N, Xu B, Wang B, Chu L, Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. Biomed Res Int. 2015;2015:126984. doi: 10.1155/2015/126984. Epub 2015 Feb 25. — View Citation

Ferguson VM, Spalton DJ. Continued breakdown of the blood aqueous barrier following cataract surgery. Br J Ophthalmol. 1992 Aug;76(8):453-6. — View Citation

Furino C, Boscia F, Niro A, Giancipoli E, Grassi MO, D'amico Ricci G, Blasetti F, Reibaldi M, Alessio G. Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema. J Ophthalmol. 2017;2017:4896036. doi: 10.1155/2017/4896036. Epub 2017 Aug 13. — View Citation

Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol. 2009 Dec;148(6):895-901.e1. doi: 10.1016/j.ajo.2009.07.014. Epub 2009 Oct 17. — View Citation

Hayashi K, Igarashi C, Hirata A, Hayashi H. Changes in diabetic macular oedema after phacoemulsification surgery. Eye (Lond). 2009 Feb;23(2):389-96. Epub 2007 Oct 26. — View Citation

Lim LL, Morrison JL, Constantinou M, Rogers S, Sandhu SS, Wickremasinghe SS, Kawasaki R, Al-Qureshi S. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results. Clin Exp Ophthalmol. 2016 May;44(4):233-42. doi: 10.1111/ceo.12720. Epub 2016 Mar 29. — View Citation

Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis. Br J Ophthalmol. 2006 Jun;90(6):697-701. Epub 2006 Mar 15. — View Citation

Rauen PI, Ribeiro JA, Almeida FP, Scott IU, Messias A, Jorge R. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina. 2012 Oct;32(9):1799-803. — View Citation

Schmier JK, Halpern MT, Covert DW, Matthews GP. Evaluation of costs for cystoid macular edema among patients after cataract surgery. Retina. 2007 Jun;27(5):621-8. — View Citation

Yumusak E, Örnek K. Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery. J Ophthalmol. 2016;2016:7945619. doi: 10.1155/2016/7945619. Epub 2016 Jul 14. — View Citation

* Note: There are 11 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of central foveal thickness outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy	Central foveal thickness will be measured in microns by spectral domain optical coherence tomography (Heidelberg) and compared to baseline at post-operative week 1, postoperative month 1, postoperative month 2, and postoperative month 3 for both anti-vascular endothelial growth factor and Ozurdex groups	3 months after cataract surgery
Secondary	Visual acuity outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy	Snellen visual acuity will be measured and converted into logMAR and compared to baseline at post-operative week 1, postoperative month 1, postoperative month 2, and postoperative month 3 for both anti-vascular endothelial growth factor and Ozurdex groups	3 months after cataract surgery